Investor Presentaiton
HLX22: Potential to Change the SOC of 1L GC
Anti-HER2 mAb
HLX22 (HER2)
•
HLX22 targets at different epitopes within domain IV of Her2
PDX data shows HLX22 & Trastuzumab combo has more
advantages than Trastuzumab & Pertuzumab combo in GC
HER2 HER1 HER2 HER3
HER2
Juhukum mikkm
HER2 HER2
•
•
Current SOC of 1L MGC/GJC treatment Trastuzumab +
chemo approved in 2010: mPFS 6.7 months, mOS 13.8
months, and mDoR 6.9 months¹
Phase II study data shows HLX22 has clear benefits for
patients, leading to great potential to change the SOC
Downstream Signal
Transduction
Pathway
Downstream Signal
Transduction
Pathway
Tumor Cell
Survival
Tumor Cell
Proliferation
Tumor Cell
Survival
Tumor Cell
Proliferation
•
HLX22 has shown better efficacy and safety
•
.
Efficacy will not be affected by the expression level of PD-L1
No observation of severe diarrhea which was observed in
other clinical trials of 1L HER2+ GC
Phase II clinical data of HLX22-GC-201 has been
presented in 2024 ASCO GI
1.Bang, Yung-Jue et al. “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer
(TOGA): a phase 3, open-label, randomised controlled trial." Lancet (London, England) vol. 376,9742 (2010): 687-97. doi: 10.1016/S0140-6736 (10) 61121-X; 2.Janjigian, Yelena Y et al. "The
KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer." Nature vol. 600, 7890 (2021): 727-730. doi: 10.1038/s41586-021-04161-3; Zanidatamab (zani), a HER2-
targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal
27 junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study. Keun Wook Lee, Li-Yuan Bai, et al Journal of Clinical Oncology 2022 40: 16_suppl, 4032-4032
2 HenliusView entire presentation